Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers

Trial StartTSY-110Positive

AI Analysis

Summary

Formosa Pharmaceuticals has filed a clinical trial application for TSY-110, an antibody-drug conjugate biosimilar targeting HER2-positive breast cancers.

Clinical Trial Data

Importance:5/10

Sentiment:

0.50

antibody-drug conjugatebiosimilarHER2-positivebreast cancerclinical trial

Related Companies

$RHHBY

Read the original article

Published by yahoo_finance on August 28, 2026 12:03 PM

Read Original